HRT prescriptions five times higher than ten years ago

NHS Business Services Authority data reveal that in 2025/2026, 16.4 million hormone replacement items were prescribed in England, up from 3.4 million items in 2016/2017.
A woman applies a hormone replacement patch to her upper arm

More than three million women in England were prescribed hormone replacement therapy (HRT) in 2025/2026, which is an almost threefold increase since 2016/2017, NHS Business Services Authority (NHS BSA) data have revealed.

Updated NHS BSA data, published on 12 November 2026, shows that the number of prescribed items rose to 16,431,889 in 2025/2026, which is almost a five-fold increase from 3,390,820 items in 2016/2017.

According to the data, the number of women prescribed HRT rose to 3,059,192 in 2025/2026, up from 1,138,221 ten years ago.

Just under one-quarter (23%) of items in 2025/2026 were obtained using an HRT prescription prepayment certificate (PPC), which were introduced in April 2023 to provide help with health costs for certain HRT medicines, the data showed.

The PPC covers an unlimited number of prescriptions for eligible medicines for 12 months, regardless of why they are prescribed.

The data also highlighted that women aged between 50 and 54 years comprised the largest cohort receiving HRT, with 663,858 identified patients.

However, there continue to be socioeconomic variations in the degree of HRT prescribing, with more than twice as many identified patients in the least deprived areas in England compared with the most deprived areas, the data suggested.

In addition, the data showed that in the most deprived quintile in England, around 31 patients per 1,000 received HRT, compared with 73 per 1,000 in the least deprived.

In a report on inequalities in HRT prescribing, published in August 2026, the NHS BSA found that in Core20 areas — the 20% most deprived areas of England — around 8.8 in every 100 women aged over 40 years receives HRT for menopause symptoms. In non-Core20 parts of the country, this figure rose to 14.2 in 100 women.

In a foreword to that report, Sue Mann, national clinical director in women’s health for NHS England, said: “It is particularly important that women who are currently least well served are not forgotten.”

“A clearer understanding of prescribing patterns can help target action where differences persist and support ongoing monitoring of change over time,” she added.

A report from the Menopause All-Party Parliamentary Group, published in October 2025, revealed “worrying disparities in both diagnosis and treatment pathways for ethnic minority women and people experiencing menopause”, adding that “Black women are five times less likely to be prescribed HRT (5.2%) compared to White women (23.3%), whilst Asian women are four times less likely (6.2%) to be prescribed it”.

A spokesperson for the British Menopause Society (BMS) said: “The BMS regards the continued increase in the number of patients receiving HRT as a positive development, to the extent that it reflects greater recognition of menopausal symptoms and improved access to effective treatment.

“However, the data do not show why prescribing has risen, nor whether it now matches clinical need. Decisions to use HRT should always follow an individualised discussion of benefits and risks, in line with NICE [National Institute for Health and Care Excellence] guideline NG23.”

“The difference in prescribing rates between the most and least deprived areas warrants attention. There is a need for further research into why this is the case,” they added.

“It could be a combination of factors, including other medical factors contributing to an avoidance of HRT prescribing by clinicians (for example, diabetes, cardiovascular comorbidity or cancer), poorer access to appointments and variation in decision-making and confidence, on the part of both providers and patients. Language barriers, cultural issues and access to evidence-based information for decision-making also play a part.”

Last updated
Citation
The Pharmaceutical Journal, PJ November 2026, Vol 317, No 8015;317(8015)::DOI:10.1211/PJ.2026.1.438570

    Please leave a comment 

    You may also be interested in